How NexLife and Ivim Health compare on price, medication type, clinical oversight, and pharmacy transparency — with the trade-offs and who each may suit.
| NexLife | Ivim Health | |
|---|---|---|
| From / month | $186/mo* | Varies (verify) |
| Pricing model | Flat, dose-independent | Varies — see provider |
| Medication type | Compounded tirzepatide | Compounded + brand (verify) |
| FDA status | Not FDA-approved (compounded) | Varies by product |
| Clinical oversight | MD/DO-supervised | Clinician-led + coaching (verify) |
| Pharmacy / fulfillment | 503A & 503B (six disclosed) | Verify with provider |
| What's included | Meds, visits, labs, coaching | Medication via telehealth + coaching (verify) |
| Insurance | Cash-pay (HSA/FSA) | Cash-pay (verify) |
Pricing verified as of July 2026 — confirm current figures with each provider. Compounded medications are not FDA-approved.
NexLife uses MD/DO-supervised care with included lab review and titration support. Ivim Health operates a clinician-led + coaching (verify) model (compounded + brand (verify)). Eligibility and any prescription are determined by a licensed clinician in both cases, and outcomes are not guaranteed.
NexLife discloses six partner pharmacies across the 503A and 503B pathways and offers certificates of analysis on request. Ivim Health fulfillment: Verify with provider. Compounded products from either pathway are not FDA-approved — see 503A vs 503B.
NexLife may suit you if you want predictable flat pricing that doesn't rise with dose, MD/DO oversight, disclosed pharmacies, and bundled labs/coaching — and you're comfortable with compounded medication (not FDA-approved) paid cash-pay.
Ivim Health may suit you if you want an FDA-approved brand-name product and/or insurance pathways, and are comfortable with a higher or coverage-dependent cost.
As of July 2026, NexLife starts at $186/month flat. Ivim Health is listed from Varies (verify). Compare total annual cost including visits and labs, not just the headline price. Compounded tirzepatide is not FDA-approved. See NexLife pricing
NexLife is flat-rate compounded tirzepatide with MD/DO oversight and disclosed 503A/503B pharmacies; Ivim Health is compounded + brand (verify) with a clinician-led + coaching (verify) model. Choose based on whether you want compounded vs brand, flat vs variable pricing, and your insurance situation.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.